With President-elect Donald J. Trump officially moving into the White House, manufacturing business leaders have quickly laid out their top priorities for his administration, eager to see substantial changes that will benefit their industry. Among the most prominent of these priorities is the
The global biopharma supply chain is on the brink of a significant shift, driven by legislative changes and economic pressures. The BIOSECURE Act and the Inflation Reduction Act (IRA) are poised to reshape the landscape and create new opportunities for India's Contract Development and
In a significant move for the oncology field, ARTBIO, Inc. has entered into a groundbreaking partnership with 3B Pharmaceuticals GmbH that aims to advance a novel alpha radioligand therapy for treating solid tumors. ARTBIO, known for its innovative AlphaDirect™ platform, focuses on 212Pb-based a
The global cell culture vessels market is on a remarkable growth trajectory, projected to expand from an estimated USD 4.90 billion in 2023 to over USD 19.65 billion by 2033. This significant growth, at a robust CAGR of 14.9% from 2024 to 2033, underscores the critical role of cell culture
The gene therapy sector, once a beacon of hope for revolutionary treatments, has seen a significant slowdown in investment post the COVID-19 pandemic. This downturn follows a period of unprecedented financial influx during the pandemic years, raising questions about the future of this promising
South Korea's pharmaceutical and biotech industry is witnessing a fascinating shift as Contract Development and Manufacturing Organizations (CDMOs) and biosimilar developers are experiencing robust growth, while traditional pharmaceutical companies lag. At the forefront of this transition is
